Characteristics and risk factors of interstitial pneumonia with autoimmune features

Respir Med. 2024 Jan:221:107500. doi: 10.1016/j.rmed.2023.107500. Epub 2023 Dec 22.

Abstract

Background: Interstitial pneumonia with autoimmune features (IPAF) has features of connective tissue disease-associated interstitial lung disease (CTD-ILD), but without meeting criteria for a specific CTD. We compared baseline characteristics, survival, and response to treatment of IPAF to both CTD-ILD and unclassifiable ILD.

Methods: Measurements were extracted from a prospective registry. Baseline features and survival were compared in IPAF against both CTD-ILD and unclassifiable ILD. Linear trajectory of lung function decline (%-predicted forced vital capacity [FVC%] and diffusion capacity of the lung for carbon monoxide [DLCO%]) before and after initiation of mycophenolate or azathioprine were compared in IPAF against both CTD-ILD and unclassifiable ILD using linear mixed models.

Results: Compared to CTD-ILD (n = 1240), patients with IPAF (n = 128) were older, more frequently male, and had greater smoking history. Compared to unclassifiable ILD (n = 665), patients with IPAF were younger, more frequently female, and had worse baseline lung function. IPAF had higher mortality compared to CTD-ILD and similar risk of mortality compared to unclassifiable ILD. Mycophenolate initiation was associated with stabilization of FVC% and DLCO% in all ILD subtypes except for FVC% in patients with IPAF, and azathioprine initiation with stabilization of FVC% and DLCO% in all ILD subtypes except for FVC% decline in IPAF and DLCO% decline in CTD-ILD.

Conclusion: Patients with IPAF had worse survival compared to those with CTD-ILD and similar mortality to unclassifiable ILD, with treatment being associated with stabilization in lung function in all three ILDs. It is uncertain whether IPAF should be considered a distinct ILD diagnostic subgroup.

Keywords: Connective tissue disease; Connective tissue disease interstitial lung disease; Interstitial lung disease; Interstitial pneumonia with autoimmune features; Unclassifiable interstitial lung disease.

MeSH terms

  • Azathioprine / therapeutic use
  • Connective Tissue Diseases* / diagnosis
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / drug therapy
  • Male
  • Risk Factors

Substances

  • Azathioprine
  • Immunosuppressive Agents